Russell Investments Group
MRKR icon

Russell Investments Group’s Marker Therapeutics MRKR Stock Holding History

Russell Investments Group’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,874
Closed -$298K – 3137
2020
Q3 		$298K Buy
+19,874
New +$363K ﹤0.01% 2610

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Russell Investments Group's MRKR Position: Q4 2020 in Review

Russell Investments Group sold out of Marker Therapeutics (MRKR) in Q4 2020, closing a stake of 19,874 shares — an estimated $298K sold.

Russell Investments Group first reported a position in MRKR in Q3 2020 and held it in 1 quarter. The position peaked at $298K in Q3 2020. 60 funds tracked by Wall St. Rank hold MRKR as of Q4 2020.

  • Russell Investments Group reported no remaining Marker Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Russell Investments Group sold 19,874 Marker Therapeutics shares in Q4 2020, an estimated $298K.
  • Russell Investments Group first reported a position in Marker Therapeutics in Q3 2020 and held it in 1 quarter.
  • Russell Investments Group's Marker Therapeutics position peaked at $298K in Q3 2020.
  • 60 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2020.

Based on Russell Investments Group's 13F filing for Q4 2020, filed 8 Feb 2021.